Sarah is developing technologies to study the contribution of aberrant DNA methylation to tumor pathogenesis

• MD/PhD student in Harvard-MIT MD/PhD Program
• Health Sciences and Technology (HST) Program at Harvard Medical School
• Systems Biology PhD program